VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS

Lawrence Steinman, MD, Stanford University, Stanford, CA, shares the results from the ULTIMATE I and II Phase III trials (NCT03277261; NCT03277248) evaluating ublituximab, a glycoengineered anti-CD20 monoclonal antibody, in relapsing multiple sclerosis (MS). The global active-controlled trials compared ublituximab to teriflunomide, assessing reduction in annualized relapse rate (ARR) over a 96-week period as the primary trial endpoint. In both studies, ublituximab demonstrated superiority over teriflunomide in reducing AARs and MRI brain lesions. Ublituximab was generally well tolerated, with no unexpected safety signals. The findings highlight ublituxmab as a highly efficacious treatment option, likely to have a place in clinical practice in the future. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Dr Steinman consults for TGTx.